0001493152-22-015353.txt : 20220527 0001493152-22-015353.hdr.sgml : 20220527 20220527161536 ACCESSION NUMBER: 0001493152-22-015353 CONFORMED SUBMISSION TYPE: AW PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220527 DATE AS OF CHANGE: 20220527 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Indaptus Therapeutics, Inc. CENTRAL INDEX KEY: 0001857044 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 863158720 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: AW SEC ACT: SEC FILE NUMBER: 333-258854 FILM NUMBER: 22977660 BUSINESS ADDRESS: STREET 1: 3 COLUMBUS CIRCLE STREET 2: 15TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 347-480-9760 MAIL ADDRESS: STREET 1: 3 COLUMBUS CIRCLE STREET 2: 15TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: Intec Parent Inc. DATE OF NAME CHANGE: 20210414 AW 1 formaw.htm

Indaptus Therapeutics, Inc.

3 Columbus Circle, 15^th Floor

New York, NY 10019

May 27, 2022

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re:	Indaptus Therapeutics, Inc.
	Registration Statement on Form S-3
	Post-Effective Amendment No. 1 dated August 16, 2021 and filed on August 16, 2021 and Post-Effective Amendment No. 1 dated August 16, 2021 and filed on August 18, 2021
	File No. 333-258854

Ladies and Gentlemen:

Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “1933 Act”), Indaptus Therapeutics, Inc. (the “Company”) hereby requests that the Securities and Commission (the “Commission”) consent to the withdrawal of (i) the Post-Effective Amendment No. 1 (SEC Accession No. 0001493152-21-020209) (the “First Post-Effective Amendment”) to the Company’s Registration Statement on Form S-3 (the “Registration Statement”), together with all exhibits filed therewith, filed on August 16, 2022, and (ii) the Post-Effective Amendment No. 1 (SEC Accession No. 0001493152-21-020550) (the “Second Post-Effective Amendment” and together with the First Post-Effective Amendment, the “Post-Effective Amendments”) to the Registration Statement, together with all exhibits filed therewith, filed on August 18, 2022. The First Post-Effective Amendment inadvertently referenced 1933 Act file number 333-258854, but when filed could not be associated with the correct 1933 Act file number 333-230016 for certain technical reasons at such time. The Second Post-Effective Amendment referenced the correct 1933 Act file number 333-230016, but when filed could still not be associated with such 1933 Act file number for technical reasons at such time. The withdrawal hereby requested is only for the Post-Effective Amendments that were filed on August 16, 2022 and on August 18, 2022, and not with respect to any other filings made under the 1933 Act file numbers 333-258854 or 333-230016. The Post-Effective Amendments have not been declared effective by the Commission and no securities have been sold under the Post-Effective Amendments.

Please direct any questions or comments regarding this correspondence to Gary Emmanuel of McDermott Will & Emery LLP at (212) 547-5541.

Thank you for your assistance in this matter.

	Very truly yours,

	INDAPTUS THERAPEUTICS, INC.

	By:	/s/ Jeffrey A. Meckler
	Name:	Jeffrey A. Meckler
	Title:	Chief Executive Officer